HOME-LUNG
CSSIFM
CSSIFM logo
Meet the Team
clinical trials
Our medical staff consists of physicians, PAs, nurses, a dietitian and a research team
request an appointment
855-797-9277
our services
learn more
CSSIFM logo
Clinical Trials
Lung Cancer Clinical Trial
Our Clinical Trials
The Enrollment Process.
clinical trials
request an appointment
855-797-9277
our services
learn more
At CSSIFM we aim to conquer cancer with innovative and individualized therapies. Anne is a pancreatic cancer survivor and continues to teach us new dance moves at each visit. Did you know that studies show routine exercise can increase your body’s ability to fight cancer by inducing engagement of IL-15. At CSSIFM we believe it is important to never lose hope and to keep moving!
Lung-NEW-slider
Lung Cancer Clinical Trial
What to Expect
Primary purpose of this study:
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm).
Trial Name
ResQ201A: Clinical Trial Of N-803 Plus Tislelizumab and Docetaxel versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer
Trial Information
Trial ID: COVID-4.019-LONG
Clinicaltrials.gov: NCT07123727
Acceptance Requirements
  1. Trial ID: ResQ201A
  2. Clinicaltrials.gov: NCT06745908
  3. Eligibility Criteria
Apply
If you are interested in screening for this trial, please click the button below:
Learn more
Lung Cancer
footer-final
Contact us
2040 East Mariposa Avenue
El Segundo, California 90245
Phone: 213-266-5600
Fax: 562-548-2304
Quick links
CSSIFM logo